About
Standards

By Category

RecoveryLongevityCognitiveMetabolicAestheticsImmuneGrowth hormoneHormonal

Popular

BPC-157NAD+GLP-2 (T)SemaxGHK-CuThymosin Alpha 1

Stacks

GLOW (skin)KLOW (immune)BPC/TB500 (recovery)CJC/Ipamorelin (GH)

Shop

All peptidesProduct certificatesSubscribe & save

Help

FAQContact us

Policies

ShippingReturns & refundsTerms & conditionsPrivacy policy
Affiliates
Earn 15% on every referral
Share OSYRIS, earn commission. Your audience gets 10% off.
Learn more →
AboutStandards
Home/Shop/Metabolic & Weight Management/GLP – 2 (T)
GLP – 2 (T) research peptide vial — OSYRIS Health
METABOLIC

GLP – 2 (T)

$99.99

GLP – 2 (T) is a synthetic peptide designed as a dual agonist of GIP and GLP-1 receptors. It is studied for its effects on glycemic control, insulin signaling, and appetite regulation in metabolic research. GLP – 2 (T) is intended strictly for laboratory research use and is not approved for human or veterinary application.

Size
Quantity15MG
FormulaC225H348N48O68
Mol. Weight~4813.45 g/mol
PuritySee COA
Free shipping on orders over $200
Download Certificate of Analysis
Research On This Compound

Tirzepatide in metabolic research

12 min read · 8 citations · Dual agonism, appetite, metabolism

COMPARISON

Tirzepatide vs Semaglutide

Dual vs single incretin agonism

COMPARISON

GLP-1 vs GLP-2 vs GLP-3

The incretin agonist progression

CATEGORY GUIDE

Metabolic peptides

Incretins, fat metabolism, exercise mimetics

DEEP DIVE

GLP-3 (R) — The triple agonist frontier

Triple agonism, energy expenditure, metabolism

Practical Guides

How to read a certificate of analysis

Peptide storage and handling

Understanding peptide purity testing

About This Compound

Product Overview

GLP-2 (T) is OSYRIS Health's designation for a dual GIP/GLP-1 receptor agonist in the tirzepatide class. Tirzepatide-class compounds represent a significant area of metabolic research because they interact with two incretin receptors simultaneously — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — rather than targeting a single receptor like semaglutide-class compounds.

The dual-agonist approach has generated substantial research interest because GIP and GLP-1 receptors regulate overlapping but distinct metabolic pathways. GLP-1 receptor activation is studied for its effects on insulin secretion, appetite signaling, and gastric emptying. GIP receptor activation is studied for its effects on fat metabolism, bone density, and glucose-dependent insulin release. Dual agonism is hypothesized to produce broader metabolic effects than single-receptor targeting.

GLP-2 (T) has a molecular weight of 4813.45 g/mol and is supplied as a lyophilized powder for reconstitution. It is intended exclusively for in vitro and preclinical metabolic research.

GLP-2 (T) metabolic receptor signaling research visualization — OSYRIS Health
Research Applications

Mechanism and Experimental Context

Tirzepatide-class compounds are studied as dual GIP/GLP-1 receptor agonists. Research published in the New England Journal of Medicine demonstrated that tirzepatide produced significant reductions in HbA1c and body weight in clinical trials for type 2 diabetes, outperforming semaglutide (a GLP-1-only agonist) on both endpoints.1 The dual-receptor mechanism is hypothesized to explain this difference — GIP receptor activation appears to enhance the metabolic effects of GLP-1 receptor activation rather than simply duplicating them.

Preclinical studies in rodent models have explored the molecular basis of this synergy. GIP receptor activation in adipose tissue appears to promote lipid metabolism through different pathways than GLP-1, suggesting the two receptors regulate complementary aspects of energy balance.2

In preclinical models, dual GIP/GLP-1 agonism has been studied for effects on glucose-dependent insulin secretion. The glucose-dependent nature of these effects is an important pharmacological property — incretin-based compounds primarily stimulate insulin release when blood glucose is elevated, which reduces the risk of hypoglycemia compared to insulin secretagogues that act independently of glucose levels.3

Research in isolated pancreatic islet cell cultures has explored the signaling mechanisms downstream of dual receptor activation, including cAMP production, calcium influx, and beta-cell proliferation pathways.

Preclinical studies in rodent models have investigated the effects of dual GIP/GLP-1 agonism on adipose tissue distribution, lean mass preservation, and energy expenditure. Research suggests that GIP receptor activation in adipocytes may influence lipid storage and mobilization through pathways distinct from GLP-1 receptor effects.4

Some research has also explored the effects of dual agonism on gastric motility and appetite signaling in animal models, investigating the relative contributions of GIP and GLP-1 receptor activation to satiety.

An emerging area of preclinical investigation examines the cardiovascular effects of dual incretin receptor agonism. GLP-1 receptor activation has established research interest in cardiovascular models, and some studies are now exploring whether GIP receptor co-activation modifies or enhances these effects.5 This is an active area of investigation with limited published data.

Explore Related Compounds

Keep the Research Trail Moving

GLP – 1 (S) research peptide vial — OSYRIS Health

GLP – 1 (S)

single GLP-1 receptor agonist (semaglutide class)

$64.99
View →
GLP – 3 (R) research peptide vial — OSYRIS Health

GLP – 3 (R)

triple agonist (retatrutide class)

$94.99 - $229.99
View →
AOD-9604 research peptide vial — OSYRIS Health

AOD-9604

studied in fat metabolism models

$49.99
View →
Referenced Studies

Source Literature

[1]

Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. PubMed: PMID 35658024

[2]

Samms RJ, et al. "GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice." Journal of Clinical Investigation, 2022. PubMed: PMID 35972793

[3]

Nauck MA, et al. "GIP and GLP-1 in type 2 diabetes — critical appraisal." Diabetes, Obesity and Metabolism, 2011. PubMed: PMID 21824233

[4]

Finan B, et al. "Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans." Science Translational Medicine, 2013. PubMed: PMID 24132637

[5]

Sattar N, et al. "Tirzepatide cardiovascular event risk assessment." Nature Medicine, 2022. PubMed: PMID 36216945

Certificate of Analysis

Batch Documentation

Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.

GLP – 2 (T) certificate of analysis

Frequently Asked Questions

Questions About GLP – 2 (T)

GLP-2 (T) is OSYRIS Health's designation for a dual GIP/GLP-1 receptor agonist in the tirzepatide class. It interacts with two incretin receptors involved in metabolic regulation. It is sold exclusively for laboratory research purposes.

These three compounds target different combinations of metabolic receptors. GLP-1 (S) is a single GLP-1 receptor agonist (semaglutide class). GLP-2 (T) is a dual GIP/GLP-1 agonist (tirzepatide class). GLP-3 (R) is a triple GIP/GLP-1/glucagon agonist (retatrutide class). Researchers study them to compare single vs. dual vs. triple receptor activation in metabolic models.

Tirzepatide (branded as Mounjaro and Zepbound) has received FDA approval as a prescription medication for specific indications. However, OSYRIS GLP-2 (T) is a research-grade compound sold exclusively for laboratory research. It is not a pharmaceutical product and is not intended for human use.

The molecular weight is 4813.45 g/mol with a molecular formula of C₂₂₅H₃₄₈N₄₈O₆₈.

Store lyophilized GLP-2 (T) at -20°C for long-term storage or 2-8°C for short-term storage. Protect from light and moisture. Once reconstituted, keep refrigerated and use within your research protocol's timeframe.

A dual agonist is a compound that activates two different receptor types simultaneously. In the case of GLP-2 (T), it activates both GIP receptors and GLP-1 receptors. Researchers study dual agonists to investigate whether targeting multiple receptors produces different effects compared to single-receptor compounds.

GIP stands for glucose-dependent insulinotropic polypeptide. It's a hormone produced in the gut that plays a role in insulin secretion and energy metabolism. GIP receptors are found on pancreatic beta cells, adipose tissue, and bone tissue.

Every batch is independently tested using HPLC and LC-MS analysis. The Certificate of Analysis for the current batch is available for download on this page.

Every Batch Tested by an Independent Lab

We publish the Certificate of Analysis for every product. See our full testing process.

See Our Standards →

All products sold by OSYRIS Health are intended for laboratory research purposes only and are not for human or veterinary use. The information provided on this page describes published scientific research and does not constitute medical advice, diagnosis guidance, or a recommendation for any specific use. Always ensure compliance with local regulations.